Partnerships & Alliances
Filter News
Found 55,342 articles
-
In a collaboration agreement announced Wednesday, Boehringer Ingelheim will gain access to Ribo’s platform to target hepatocytes with investigational siRNA therapies for nonalcoholic or metabolic dysfunction-associated steatohepatitis. -
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
1/3/2024
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates.
-
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
1/3/2024
BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced today a strategic collaboration and licensing agreement with Galapagos NV (Euronext & NASDAQ: GLPG).
-
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
1/3/2024
MaxCyte, Inc. today announced the signing of a strategic platform license (SPL).
-
K2 Medical Research Join Forces with Magruder Eye Institute to Advance Alzheimer's Clinical Trial Accessibility Through RetiSpec's AI-Driven Eye Test
1/3/2024
K2 Medical Research, a privately-owned clinical research facility in the greater Orlando area, has teamed up with Magruder Eye Institute and RetiSpec in a research pilot to enhance access to clinical trials.
-
HEALTH CANADA APPROVES PFIZER CANADA'S GENE THERAPY IN HEMOPHILIA B
1/3/2024
Pfizer Canada ULC announced that Health Canada approved BEQVEZ (fidanacogene elaparvovec), an adeno-associated viral (AAV) vector-based gene therapy for the treatment of adults (aged 18 years or older) with moderately severe to severe hemophilia B.
-
SEKISUI Diagnostics and Aptitude Partner to Provide Metrix™ COVID-19 Tests to the Point-of-Care and Home Test Markets
1/3/2024
SEKISUI Diagnostics, a global medical diagnostics manufacturer, has formalized an exclusive distribution agreement with Aptitude Medical Systems (Aptitude™), an innovative developer of decentralized molecular diagnostics, to sell the Aptitude Metrix™ COVID-19 Test in the U.S.
-
Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides
1/3/2024
Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), announced today that is has signed an exclusive license agreement with Tufts University (“Tufts”) to develop and commercialize patented technology covering 18 unique collagen peptides.
-
MediKarma and Arkos Health Enter Strategic Partnership to Support Patients to Better Manage Their Health and Improve Chronic Conditions
1/3/2024
MediKarma today announced that the company has recently entered into a strategic partnership with Arkos Health. On December 1st 2023, the two organizations launched a six-month value-based care pilot program with the goal of generating healthier outcomes for individuals using MediKarma's patient learning and engagement platform.
-
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors
1/3/2024
NorthStar Medical Radioisotopes, LLC and Curadh MTR Inc. announced a long-term strategic collaboration to develop and produce novel radiopharmaceuticals for the diagnosis and treatment of solid tumor cancers.
-
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
1/3/2024
Better Therapeutics Inc. and Glooko, Inc. today announced a partnership to integrate Better Therapeutics’ AspyreRx ™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.
-
TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration
1/3/2024
TRex Bio, Inc. today announced that Johnson & Johnson Innovative Medicine has exercised the first of its options for an exclusive license to develop and commercialize a program arising out of the parties’ collaboration.
-
Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing
1/3/2024
Remix Therapeutics (Remix) today announced a collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
-
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
1/3/2024
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT) and Arbor Biotechnologies, Inc. (Arbor) today announced a strategic partnership focused on advancing new AAV-based gene-editing therapies for central nervous system (CNS) diseases with high unmet medical needs in both rare and common disease populations.
-
The Swiss pharma is looking to leverage Voyager Therapeutics’ capsid technology for gene therapies aimed at treating Huntington’s disease and spinal muscular atrophy. -
The antibody-drug conjugate market remains hot so far in 2024 with Tuesday’s collaboration and license agreement between Roche and MediLink Therapeutics to develop a next-generation ADC in oncology. -
Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications
1/2/2024
Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation (A063160.KS) for CKDB-501, a neuromodulator BoNT/A protein.
-
MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to develop next-generation antibody drug conjugate in Oncology
1/2/2024
MediLink Therapeutics ("MediLink"), announced today that it has entered into a worldwide collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.
-
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
1/2/2024
Voyager Therapeutics, Inc. today announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS) to advance potential gene therapies for Huntington’s disease (HD) and spinal muscular atrophy (SMA).
-
SimBioSys and Mayo Clinic Enter Strategic Collaboration to Advance AI-powered Digital Precision Medicine Platform for Cancer Patients
1/2/2024
SimBioSys announced today it has entered into a strategic collaboration agreement with Mayo Clinic for the development of novel digital precision medicine solutions for breast cancer patients.